ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Short Communication



Use of propranolol in children with primary nocturnal enuresis

Huseyin Caksen, Pinar Yazicioglu, Bulent Atas.



Abstract
Download PDF Post

In nocturnal enuresis motivational therapy, alarm therapy and drug therapy such as anticholinergics, imipramine and sertraline are the mainstay of treatment. In this study, we used motivational therapy, oxybutynin and propranolol in children with primary nocturnal enuresis to determine if propranolol is effective in the treatment of primary nocturnal enuresis. Fifty two children with primary nocturnal enuresis were included in the study. Firstly, motivational motivational therapy was given for 1 month in all patients. Patients who failed by motivational therapy were randomly given oxybutynin or propranolol. The patients were re-evaluated after 1 month of drug therapy. There was not a significant difference between oxybutynin and propranolol groups for initial frequency of nocturnal enuresis (P >0.05). Of 52 patients, 28 (53.8%) patients were improved by motivational therapy. There were 14 patients in oxybutynin group. One patient was excluded from the study because facial flushing and mouth drying developed in the first week of oxybutynin therapy. In oxybutynin group, 12 (92.3%) of 13 patients were improved. There were 10 patients in propranolol group. In propranolol group, while nine (90%) patients were not improved, one patient had significant remission (90%) (P

Key words: Primary enuresis nocturna; Child; Motivational therapy; Oxybutynin; Propranolol







Bibliomed Article Statistics

34
25
22
38
24
32
28
28
13
17
23
20
R
E
A
D
S

19

19

9

11

7

11

16

16

8

9

9

13
D
O
W
N
L
O
A
D
S
010203040506070809101112
2025

Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.